IP Library Granted Patent US 9,206,477
Granted Patent B2
US 9,206,477 · App. 14/513,906 · Granted Dec 8, 2015

Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays

Inventors: Francis Barany (New York, NY); George Barany (Falcon Heights, MN); Robert P. Hammer (Acton, MA); Maria Kempe (Malmo, SE); Herman Blok (Wemeldinge, NL); Monib Zirvi (Monmouth Junction, NJ)
Assignee: Cornell Research Foundation, Inc.
C12Q1/6876B01J19/0046B82Y30/00C12Q1/6816C12Q1/6827C12Q1/6837B01J2219/0059B01J2219/0061B01J2219/00432B01J2219/00527B01J2219/00529B01J2219/00536B01J2219/00585B01J2219/00596B01J2219/00605B01J2219/00608B01J2219/00612B01J2219/00621B01J2219/00626B01J2219/00637B01J2219/00659B01J2219/00711B01J2219/00722B01J2219/00729C12Q2600/156C40B40/06C40B60/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,206,477
App. No.
14/513,906
Granted
Dec 8, 2015
Kind
B2
Abstract

The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support.

Claims (26)

1. A group of beads, wherein each bead of the group comprises one type of capture oligonucleotide from a collection of capture oligonucleotides, wherein each type of capture oligonucleotide is 20-24 nucleotides in length, and wherein each type of capture oligonucleotide comprises a nucleotide sequence that differs from the nucleotide sequence of other types of capture oligonucleotides of the collection by at least 25% when aligned, and wherein each capture oligonucleotide in the collection hybridizes to a nucleic acid molecule comprising a complementary nucleotide sequence under uniform hybridization conditions, wherein hybridized capture oligonucleotides comprise a melting temperature (T m ) that is >55° C. when calculated using the formula T m =4(G+C)+2(A+T) ° C.

2. The group of beads of claim 1 , wherein each type of capture oligonucleotide hybridizes to the nucleic acid molecule comprising a complementary nucleotide sequence at a temperature of 60° C.

3. The group of beads of claim 1 , wherein each type of capture oligonucleotide hybridizes to the nucleic acid molecule comprising a complementary nucleotide sequence at a temperature of 65° C.

4. The group of beads of claim 1 , wherein each type of capture oligonucleotide hybridizes to the nucleic acid molecule comprising a complementary nucleotide sequence at a temperature of 70° C.

5. The group of beads of claim 1 , wherein each type of capture oligonucleotide is 24 nucleotides in length.

6. The group of beads of claim 1 , wherein the beads are configured on an addressable array.

7. The group of beads of claim 1 , wherein each type of capture oligonucleotide within the collection of oligonucleotides exhibits minimal cross-hybridization to a complement of another type of capture oligonucleotide within the collection at 35° C.

8. The group of beads of claim 1 , wherein each type of capture oligonucleotide has a sequence configured to hybridize to the nucleic acid molecule having a complementary nucleotide sequence when incubated for 15 minutes at 60° C. in a solution comprising 0.5 M Na 2 HPO 4 having a pH of 7.2, 1% BSA, 1 mM EDTA, and 7% SDS.

9. The group of beads of claim 8 , wherein each type of capture oligonucleotide has a sequence configured to remain hybridized to its complementary nucleic acid molecule following washing at 60° C. in a low stringency wash buffer comprising 300 mM sodium chloride, 30 mM sodium citrate, and 0.1% SDS, and washing at 60° C. in a high stringency wash buffer comprising 30 mM sodium chloride, 3 mM sodium citrate, and 0.1% SDS.

10. The group of beads of claim 8 , wherein each type of capture oligonucleotide has a sequence configured to remain hybridized to its complementary nucleic acid molecule following washing at 65° C. in a low stringency wash buffer comprising 300 mM sodium chloride, 30 mM sodium citrate, and 0.1% SDS, and washing at 65° C. in a high stringency wash buffer comprising 30 mM sodium chloride, 3 mM sodium citrate, and 0.1% SDS.

11. The group of beads of claim 8 , wherein each type of capture oligonucleotide has a sequence configured to remain hybridized to its complementary nucleic acid molecule following washing at 70° C. in a low stringency wash buffer comprising 300 mM sodium chloride, 30 mM sodium citrate, and 0.1% SDS, and washing at 70° C. in a high stringency wash buffer comprising 30 mM sodium chloride, 3 mM sodium citrate, and 0.1% SDS.

12. The group of beads of claim 1 , wherein each type of capture oligonucleotide has a sequence configured to hybridize to the nucleic acid molecule having a complementary nucleotide sequence when incubated for 15 minutes at 65° C. in a solution comprising 0.5 M Na 2 HPO 4 having a pH of 7.2, 1% BSA, 1 mM EDTA, and 7% SDS.

13. The group of beads of claim 1 , wherein each type of capture oligonucleotide has a sequence configured to hybridize to the nucleic acid molecule having a complementary nucleotide sequence when incubated for 15 minutes at 70° C. in a solution comprising 0.5 M Na 2 HPO 4 having a pH of 7.2, 1% BSA, 1 mM EDTA, and 7% SDS.

14. A group of beads, wherein each bead of the group comprises one type of capture oligonucleotide from a collection of capture oligonucleotides, wherein each type of capture oligonucleotide is 20-24 nucleotides in length and comprises a guanosine/cytosine (GC) content that is >50%, and wherein each type of capture oligonucleotide comprises a nucleotide sequence that differs from the nucleotide sequence of other types of capture oligonucleotides of the collection by at least 25% when aligned, and wherein each capture oligonucleotide in the collection hybridizes to a nucleic acid molecule comprising a complementary nucleotide sequence under uniform hybridization conditions.

15. The group of beads of claim 14 , wherein each type of capture oligonucleotide hybridizes to the nucleic acid molecule comprising a complementary nucleotide sequence at a temperature of 60° C.

16. The group of beads of claim 14 , wherein each type of capture oligonucleotide hybridizes to the nucleic acid molecule comprising a complementary nucleotide sequence at a temperature of 65° C.

17. The group of beads of claim 14 , wherein each type of capture oligonucleotide hybridizes to the nucleic acid molecule comprising a complementary nucleotide sequence at a temperature of 70° C.

18. The group of beads claim 14 , wherein each type of capture oligonucleotide is 24 nucleotides in length.

19. The group of beads of claim 14 , wherein the beads are configured on an addressable array.

20. The group of beads of claim 14 , wherein each type of capture oligonucleotide within the collection of oligonucleotides exhibits minimal cross-hybridization to a complement of another type of capture oligonucleotide within the collection at 35° C.

21. The group of beads of claim 14 , wherein each type of capture oligonucleotide has a sequence configured to hybridize to a nucleic acid molecule having a complementary nucleotide sequence when incubated for 15 minutes at 60° C. in a solution comprising 0.5 M Na 2 HPO 4 having a pH of 7.2, 1% BSA, 1 mM EDTA, and 7% SDS.

22. The group of beads of claim 21 , wherein each type of capture oligonucleotide has a sequence configured to remain hybridized to its complementary nucleic acid molecule following washing at 60° C. in a low stringency wash buffer comprising 300 mM sodium chloride, 30 mM sodium citrate, and 0.1% SDS, and washing at 60° C. in a high stringency wash buffer comprising 30 mM sodium chloride, 3 mM sodium citrate, and 0.1% SDS.

23. The group of beads of claim 21 , wherein each type of capture oligonucleotide has a sequence configured to remain hybridized to its complementary nucleic acid molecule following washing at 65° C. in a low stringency wash buffer comprising 300 mM sodium chloride, 30 mM sodium citrate, and 0.1% SDS, and washing at 65° C. in a high stringency wash buffer comprising 30 mM sodium chloride, 3 mM sodium citrate, and 0.1% SDS.

24. The group of beads of claim 21 , wherein each type of capture oligonucleotide has a sequence configured to remain hybridized to its complementary nucleic acid molecule following washing at 70° C. in a low stringency wash buffer comprising 300 mM sodium chloride, 30 mM sodium citrate, and 0.1% SDS, and washing at 70° C. in a high stringency wash buffer comprising 30 mM sodium chloride, 3 mM sodium citrate, and 0.1% SDS.

25. The group of beads of claim 14 , wherein each type of capture oligonucleotide has a sequence configured to hybridize to a nucleic acid molecule having a complementary nucleotide sequence when incubated for 15 minutes at 65° C. in a solution comprising 0.5 M Na 2 HPO 4 having a pH of 7.2, 1% BSA, 1 mM EDTA, and 7% SDS.

26. The group of beads of claim 14 , wherein each type of capture oligonucleotide has a sequence configured to hybridize to a nucleic acid molecule having a complementary nucleotide sequence when incubated for 15 minutes at 70° C. in a solution comprising 0.5 M Na 2 HPO 4 having a pH of 7.2, 1% BSA, 1 mM EDTA, and 7% SDS.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 8, 2018
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045289/0544 →
CONFIRMATORY LICENSE Recorded Oct 20, 2014
From: CORNELL UNIVERSITY / CORNELL RESEARCH FOUNDATION, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034015/0245 →
Continuity (7)
Continuation 14101067 · Dec 9, 2013
Continuation 13229198 · Sep 9, 2011
Continuation 13072442 · Mar 25, 2011
Continuation 10854678 · May 25, 2004
Continuation 08794851 · Feb 4, 1997
Provisional Application 60011359 · Feb 9, 1996
Related Publication 20150038374A1 · Feb 5, 2015